Free Trial
→ Trump’s issues shocking Executive Order on U.S. Dollar (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:PMCB

Nuvilex Q1 2027 Earnings Results & Report

Nuvilex logo
$0.41 +0.01 (+2.16%)
As of 10/9/2026 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Nuvilex missed analyst earnings expectations in its Q1 2027 results, released September 14, 2026. The company reported EPS of -$0.54 versus the -$0.06 consensus estimate.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q1 2027
Report Date
Time
Before Market Opens

Nuvilex EPS Results

Actual EPS
-$0.54
Consensus EPS
-$0.06
Beat/Miss
Missed by -$0.48
One Year Ago EPS
N/A

Nuvilex Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Nuvilex's next earnings date is estimated for Wednesday, December 16, 2026, based on past reporting schedules.

Conference Call Resources

Nuvilex Q1 2027 Earnings FAQ

Nuvilex (NASDAQ:PMCB) reported earnings of -$0.54 per share for Q1 2027, missing the consensus estimate of -$0.06. The report was announced on Monday, September 14, 2026.

Nuvilex's next earnings date is estimated for Wednesday, December 16, 2026. MarketBeat tracks confirmed and estimated earnings dates for Nuvilex on the company's earnings history page.

Nuvilex Earnings Headlines

Nuvilex (NASDAQ:PMCB) Shares Down 2.5% - Here's Why
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31090161
PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
September 2, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250902025594/en/pharmacyte-biotech-inc.-increases-stake-in-tnf-pharmaceuticals-around-recent-license-for-breakthrough-light-speed-computing-platform-for-use-in-cryptocurrency-applications/
No. 1 stock to cash in on the death of iPhone
Analyst Josh Baylin, who warned Congress about smartphones years before the iPhone launched, says the world's richest man may be building an iPhone rival he calls Starphone. Baylin points to FCC rulings, two trademarks filed the same day, multibillion-dollar spectrum deals, chip partnerships, and a string of posts from Elon Musk as evidence pointing to one conclusion. See the full research and the stock Baylin is watching now.tc pixel
 |  Stansberry Research (Ad)
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
August 20, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250820055624/en/PharmaCyte-Biotech-Inc.-Announces-Closing-of-7-Million-Financing/
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors
August 18, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250818528622/en/pharmacyte-biotech-inc.-announces-7-million-capital-raise-led-by-existing-investors/
MyMD Pharmaceuticals Secures Strategic Investments
May 21, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20240521024499/en/mymd-pharmaceuticals-secures-strategic-investments/
See More Nuvilex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvilex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvilex and other key companies, straight to your email.

About Nuvilex

Nuvilex (NASDAQ:PMCB), Inc. was a biotechnology company that developed therapies for cancer and other serious diseases. The company focused on combining cellular therapy with drug-delivery technologies intended to provide localized treatment while limiting exposure to healthy tissue.

Its principal program involved the Cell-in-a-Box technology, which uses encapsulated genetically engineered cells to convert certain chemotherapy prodrugs into active cancer-fighting compounds at or near a tumor. Nuvilex applied this approach primarily to pancreatic cancer, including a planned treatment regimen involving encapsulated cells and ifosfamide.

Nuvilex later changed its name to PharmaCyte Biotech, Inc. and continued development of the Cell-in-a-Box platform under the PharmaCyte Biotech name. Publicly available information about Nuvilex’s operations, geographic reach, and leadership is primarily historical because the company no longer operates under the Nuvilex name.

View Nuvilex Profile
Earnings Tools